H.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience (LEXX) shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as planned. The GLP-1-H24-4 study includes four planed DehydraTECH formulation arms and one Rybelsus comparator control arm and is slated to enroll 20 20 overweight, obese, pre- or type 2 diabetic patients for each of arms 1-4 at seven clinical sites, with the DehydraTECH-tirzepatide Arm 5 to be added at a later date if supported by positive results from the separate ongoing study GLP-1- H24-3, the analyst tells investors in a research note. Positive results from this study could expand the application of the DehydraTECH delivery technology in the GLP-1 sector, the firm says.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.